PAR Tech receives two 'PeopleFirst HR Excellence Award 2025'
"These accolades stand as a strong endorsement of PAR's commitment to fostering a positive impact, both within the organization and in the broader community," said Ritesh Chhabra, Vice President and India Head at PAR Tech, who, along with his leadership colleague Ms. Bineeta Anand, Head of HR-India, attended this event in Dubai to receive this award.
He further added, "We at PAR are committed to build a people-first culture and giving back to the society - our well-designed Corporate Social Responsibility Programs effectively deployed in Jaipur are deeply rooted to make the difference and a positive impact for the collective social growth in education sector. The PeopleFirst Excellence Awards are a testament to the great work delivered by all the colleagues and our people-first practices," said Mr. Chhabra, expressing gratitude to PeopleFirst for the recognition.
Mr. Chhabra also participated in a panel discussion on "The Importance of Micro-Cultures in a Global Organization," where he shared insights from his journey of building and sustaining a 'One Team' culture at PAR. He spoke about the importance of defining clear outcomes, breaking down functional and geographical barriers, and leading with empathy-principles that have helped foster a cohesive and high-performing global team.
The PeopleFirst HR Excellence Awards 2025 celebrate the most impactful HR initiatives by organizations globally. Recognized as a seminal event in the HR space, the awards attract top individuals, teams, and companies across geographies and industries. This year, over 100 entries were received from organizations across diverse sectors, including manufacturing, automotive, telecom, IT, banking, financial services, and insurance.
The jury praised the strength of PAR Tech's nomination and presentation. According to the award team, the jury feedback highlighted the company's dedication, innovation, and zeal for excellence in the HR domain.
Headquartered in New York, USA, PAR Technology operates across multiple countries, including two key centres in India- Jaipur and Gurugram. For over 40 years, PAR has delivered solutions in software, hardware, and services to leading global restaurant chains and franchisees. Today, its offerings span the full spectrum of hospitality—from independent table-service restaurants to international QSR chains and luxury resorts—all backed by a global service network. With nearly 100,000 installations in 110 countries, PAR continues to transform the hospitality industry through technology.
PAR Technology Corporation is publicly traded on the New York Stock Exchange under the symbol 'PAR'.
(Disclaimer: The above press release comes to you under an arrangement with PRNewswire and PTI takes no editorial responsibility for the same.). PTI PWR
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
9 hours ago
- Economic Times
Is Novo Nordisk facing its 'Nokia moment'? Stock tumbles to $50 from a year-high of $139 amid disruptive rivals and shifting market forces
Reuters Novo Nordisk, Denmark's pharma powerhouse, has seen its stock plunge from record highs as fierce competition, slowing growth, and market shifts test its dominance in the global diabetes and obesity drug market. Novo Nordisk (NYSE: NVO) closed at $50.39 on Thursday, down $0.51 (-1%), extending its staggering decline from a year-high of $139.74. Investors are questioning whether the Danish pharmaceutical giant is approaching its own 'Nokia moment'—a pivotal inflection point where market dominance is challenged by nimble competitors and shifting industry dynamics. On July 29, 2025, Novo Nordisk lowered its full-year 2025 sales growth forecast from 13–21% to 8–14%. Operating profit (EBIT) growth was also trimmed to 10–16% from 16–24%. The announcement triggered a 20–30% single-day stock plunge, wiping out roughly $70 billion in market capitalization. Investors had expected continued dominance in the lucrative obesity and diabetes markets, but the downgrade sent an unmistakable warning: growth is slowing, and the competitive landscape is shifting rapidly. Novo Nordisk's blockbuster drugs Wegovy and Ozempic have faced growing headwinds: Compounded versions from U.S. pharmacies —driven by FDA shortages—have eaten into branded sales. —driven by FDA shortages—have eaten into branded sales. Eli Lilly's Zepbound and Mounjaro are gaining prescription share. As of July 2025, Zepbound holds 59% of prescriptions compared to Wegovy's 40%, signaling a material shift in market preference. These trends highlight a dual threat: traditional competition and unregulated compounding pharmacies undermining pricing power. Longtime CEO Lars Fruergaard Jørgensen stepped down on August 7, 2025, passing the reins to Maziar Mike Doustdar. The new CEO faces immediate challenges: stabilizing sales, defending market share, and restoring investor confidence. Market watchers emphasize that leadership changes at such a sensitive moment can either signal a bold strategic pivot or deepen uncertainty, depending on how quickly Doustdar asserts his vision. Novo Nordisk is also navigating U.S. legal scrutiny. A class-action lawsuit claims the company misled investors about competitive risks and overstated growth prospects. Financial institutions are taking note: UBS downgraded NVO to 'neutral' and cut its target price from 600 to 340 Danish kroner, warning that competitive and compounding pressures are 'here to stay.' Market opinion is divided. Some analysts foresee additional downside, while others highlight support near $47.50 as a potential stabilization point. Contributors on Seeking Alpha argue that the sell-off may have priced in worst-case scenarios, leaving room for a measured recovery if Novo's R&D pipeline delivers next-generation weight-loss drugs or accelerates global expansion. Novo Nordisk started its journey in Denmark in the 1920s, when two small companies—Nordisk and Novo—were founded to make insulin for people with diabetes. In 1989, the two merged to form Novo Nordisk as we know it today. The company's largest owner is the Novo Nordisk Foundation, which holds nearly a third of the shares but controls more than three-quarters of the voting rights. Headquartered in Bagsværd, just outside Copenhagen, Novo Nordisk has grown into one of the world's most valuable pharmaceutical companies. In mid-2025, it's worth around $305 billion, although last year it briefly touched almost $600 billion, putting it among the most valuable companies on the planet. At home, its impact is hard to overstate. Novo Nordisk is Denmark's biggest taxpayer, a major exporter, and an economic powerhouse—at one point its market value was larger than Denmark's entire GDP. Today, it's not just a national success story but a global leader in diabetes, obesity, and rare disease treatments. Despite short-term headwinds, Novo Nordisk is pursuing multiple growth avenues: Amycretin – Dual-Action Obesity Drug: Phase 1b/2a trials show 22% average body weight loss over 36 weeks, sparking a ~12% stock bump. CagriSema – Record Weight Loss in Phase III: Achieved 20.4% weight reduction in obese adults and 13.7% in type 2 diabetes patients. Oral Semaglutide & Amycretin: Oral formulations are under U.S. regulatory review, potentially broadening adoption. $2.2B Septerna Partnership: Four programs targeting obesity, type 2 diabetes, and cardiometabolic diseases. Insulin Icodec (Awiqli) – Once-Weekly Insulin: Approved in Canada, EU, and Japan, improving patient adherence. NNC2215 – Glucose-Sensitive 'Smart' Insulin: Adjusts activity based on blood sugar, reducing hypoglycemia risk. Alhemo (Concizumab) – Hemophilia Treatment: FDA-approved July 2025 for A and B types. AI and Rare Disease Expansion: Collaborations with Heartseed, Ventus Therapeutics, and megaTAL platform targeting cardiovascular, MASH, and CKD therapies. These developments suggest Novo's core capabilities remain strong, providing potential long-term catalysts. Not exactly. While Novo Nordisk faces heightened competition, slowing growth, leadership changes, and legal pressures, it retains robust cash flows, a dominant market footprint, and a promising pipeline. Short-term turbulence is clear. Yet a full-scale Nokia-style collapse is unlikely given Novo's strategic assets and global reach. The company is navigating a near-term storm, but its innovation engine and expansion efforts leave the door open for recovery. Indicator Status Sales & Profit Guidance Significantly lowered; investor reaction strongly negative Competition & Market Threats Rising; compounded drugs and Eli Lilly products erode share Leadership & Strategy New CEO; strategic clarity still evolving Legal & Regulatory Risks Class-action lawsuit; compounding disputes add uncertainty Valuation & Sentiment Deeply discounted; mix of caution and opportunistic value Long-term Outlook Not terminal; pipeline and global expansion offer growth levers Defensive stance: Exercise caution until guidance execution and competitive dynamics are clearer. Exercise caution until guidance execution and competitive dynamics are clearer. Value opportunity: Contrarian investors may view the sharp dip as a long-term buying chance, particularly if Novo can regain share and deliver on pipeline milestones. Contrarian investors may view the sharp dip as a long-term buying chance, particularly if Novo can regain share and deliver on pipeline milestones. Catalysts to watch: CEO performance, legal outcomes, regulatory action on compounding, and international R&D breakthroughs. Novo Nordisk is at a critical crossroads. The company isn't collapsing, but it's clear that the weight-loss and diabetes markets are no longer uncontested territory. How the company navigates competition, regulation, and innovation in the coming months will determine whether this is a temporary stumble—or the start of a deeper transformation. Q1: What caused the Novo Nordisk stock plunge recently? A1: The stock fell after 2025 sales guidance cuts and rising competition from Eli Lilly drugs and compounded versions. Q2: How is Wegovy Ozempic market pressure affecting Novo Nordisk? A2: Competing drugs and pharmacy compounding have reduced market share and investor confidence.
Hans India
10 hours ago
- Hans India
IBM unveils new India Client Experience Centre in Mumbai and announces plans to support Government of Maharashtra's Quantum Initiatives
Today, IBM (IBM: NYSE) announced the opening of the company's new IBM India Client Experience Center in Mumbai. As part of the facility's mission to support Indian enterprises' use of AI, hybrid cloud, and quantum computing, the company has signed a Letter of Intent (LOI) with the Government of Maharashtra to identify opportunities of support for the state's quantum initiatives. The LOI outlines areas of exploration that may include providing insight, knowledge, and expertise the state may use to help craft its own quantum initiative, and contributing to the development of the state's quantum ecosystem through workshops and other skills development efforts. Inaugurating the center, Shri Devendra Fadnavis, Hon'ble Chief Minister of Maharashtra said, 'With AI, quantum computing, and semiconductors, we are building a Viksit Maharashtra and Viksit Bharat. These technologies can accelerate sustainability and efficiency across sectors, creating new opportunities for growth and progress. Through our collaboration with IBM, we will harness quantum innovation to transform lives, while building a skilled talent pool to democratize its benefits and make them accessible to every citizen of the state.' Hans Dekkers, General Manager, IBM Asia Pacific said, 'IBM India Client Experience Centre reinforces our commitment in helping advance India's journey in AI, hybrid cloud, and quantum computing. Our interest in helping the Government of Maharashtra build their own vibrant quantum ecosystem exemplifies our commitment.' 'IBM welcomes the opportunity to engage with the Government of Maharashtra on advancing quantum computing skills in the state, in alignment with the country's National Quantum Mission, and vision of Viksit Bharat,' said Sandip Patel, Managing Director, IBM India and South Asia.
The Wire
14 hours ago
- The Wire
Technology sector anchors ~40% office leasing while global enterprises expand India operations: Colliers
• Over half of the total leasing across the top 7 cities led by large-sized deals • Tech occupiers continue to drive majority of the large-sized deals • Bengaluru and Hyderabad drive close to half of the Pan India tech demand BENGALURU, India, Aug. 14, 2025 /PRNewswire/ -- Large-sized deals (≥100,000 sq. ft.), continue to drive India's commercial office market, consistently accounting for bulk of the Grade A office space uptake in the last 5 years. In H1 2025 too, 51% of the total leasing across the top 7 cities was through large-sized deals at 17.2 million sq feet, reflecting occupiers' sustained appetite for high-quality office spaces to support growth strategies. Trends in office leasing across deal sizes (2020- H1 2025) 2020 2021 2022 2023 2024 H1 2025 Total gross leasing in mn sq ft 30.3 33.0 50.3 58.2 67.2 33.7 Large sized deals (≥100,000 sq ft) 65 % 50 % 46 % 49 % 53 % 51 % Medium sized deals (50,000–100,000 sq ft) 14 % 15 % 17 % 16 % 15 % 20 % Small sized deals (
